bioMerieux said that it has signed an agreement with GlaxoSmithKline Plc. (GSK, GSK.L) to develop a predictive test to help clinicians select the most appropriate treatment for different segments of breast cancer patients. This test, based on emerging biomarkers, will be intended for use in both adjuvant and metastatic breast cancer settings, subject to regulatory approvals. Over 500,000 new cases of breast cancer are diagnosed each year in the US and Europe alone and predictive tests have been shown to improve outcomes for these patients.
The development of this new test will be co-funded by both companies and will leverage their complementary expertise. The new test will be developed by bioMerieux's global R&D team, including its subsidiary, bioTheranostics.
For comments and feedback: editorial@rttnews.com